P224 REAL-WORLD EVIDENCE OF IMPROVED PATIENT OUTCOMES WITH RESLIZUMAB IN ADULTS WITH SEVERE EOSINOPHILIC ASTHMA (SEA)

Reslizumab, an anti-interleukin-5 antibody, is approved in the U.S. as add-on therapy for patients with SEA, who typically have elevated eosinophil levels, impaired lung function, and increased risk of clinical asthma exacerbations (CAEs). This study assessed real-world outcomes associated with reslizumab in U.S. clinical practice.